Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Stay Ahead of the ...

Zoryve (roflumilast) is a brand-name drug that’s prescribed for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in adults and some children. Zoryve comes as a topical cream or ...

psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...